Teva Shares Phase 3 SPACE Trial Results Highlighting The Efficacy And Safety Of AJOVY (Fremanezumab) In Preventing Episodic Migraine In Children And Adolescents

Teva股票的第三阶段SPACE试验结果突显AJOVY（Fremanezumab）在预防儿童和青少年发作性偏头痛中的疗效和安全性

Benzinga · 12/04 01:20

AJOVY (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years1
Efficacy consistent with fremanezumab pivotal Phase 3 and Real-World Evidence studies in adults with no new emergent safety signals observed
Full data presented as a late breaker at European Headache Cosgress (EHC) 4-7 December in Rotterdam, Netherlands

AJOVY（fremanezumab）在12周内显著减少了6-17岁的小儿患者的每月偏头痛天数（MMD）和每月头痛天数（MHD），与安慰剂相比。
疗效与成人中fremanezumab关键第3阶段和现实世界证据研究一致，未观察到新的紧急安全信号。
完整数据将于12月4日至7日在荷兰鹿特丹举行的欧洲头痛大会（EHC）上作为一项晚期突击发表。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息